The Effect of Ultrapure Dialysate on Clinical Outcomesand Mortality During One Year Follow-up in PatientsUndergoing Hemodialysis Treatment
Yıl: 2020 Cilt: 29 Sayı: 3 Sayfa Aralığı: 205 - 211 Metin Dili: İngilizce DOI: 10.5152/turkjnephrol.2020.3979 İndeks Tarihi: 01-06-2021
The Effect of Ultrapure Dialysate on Clinical Outcomesand Mortality During One Year Follow-up in PatientsUndergoing Hemodialysis Treatment
Öz: Objective: We investigated the relationship between mortality and clinical status in patients with hemodialysis using ultrapure dialysate and standard dialysate.Materials and Methods: The study included 81 patients using ultrapure dialysate (Group 1) and 72 patients using standard dialysate (Group 2). Mortality rates, anemia, phosphorus, albumin, parathormone, and C-reactive protein (CRP) values were calculated as 1-year averages. Factors affecting mortality were evaluated by logistic regression analysis.Results: In Group 1, potassium, phosphorus, uric acid, CRP, and hemoglobin levels were significantly higher (p<0.001, p=0.023, p=0.010, p=0.003, p<0.001, respectively), and transferrin saturation, ferritin, and HCO3− levels were significantly lower (p=0.007, p<0.001, p=0.001, respectively) than Group 2. The erythropoietin-stimulating agent’s usage dose of Group 1 was 0.60 (0.11-1.00) μg/kg/month and 1.30 (0.80-2.17) μg/kg/month in Group 2 (p<0.001). Iron usage doses of Group 1 and Group 2 were 800 (425-1,275) mg/year and 1,300 (750-2,000) mg/year, respectively (p=0.002). There was no significant difference in mortality rates for the 1-year follow-up period (mortality rate in 12 patients [14.8%] in Group 1, 6 patients in Group 2 [8.9%], p=0.214). In the univariate and multivariate logistic regression analyses, age, serum Na, total protein, and CRP levels were found to be independent variables to determine mortality.Conclusion: After 1 year of short-term follow-up, Group 1 had better anemia control than Group 2 but no positive effect on mortality.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1 Kwan BC, Chow KM, Ma TK, Cheng PM, Leung CB, Li PK, et al. Effect of using ultrapure dialysate for hemodialysis on the level of circulating bacterial fragment in renal failure patients. Nephron Clin Pract 2013; 123: 246-53. [Crossref]
- 2. Bommer J, Jaber BL. Ultrapure dialysate: Facts and myths. Semin Dial 2006; 19: 115-9. [Crossref]
- 3. Ledebo I, Nystrand R. Defining the microbiological quality of dialysis fluid. Artif Organs 1999; 23: 37-43. [Crossref]
- 4. Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998; 54: 627- 36. [Crossref]
- 5. McIntyre CW, Harrison LE, Eldehni MT, Jefferies HJ, Szeto CC, John SG, et al. Circulating endotoxemia: A novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 133-41. [Crossref]
- 6. Morena M, Cristol JP, Canaud B. Why hemodialysis patients are in a prooxidant state? What could be done to correct the pro/antioxidant imbalance? Blood Purif 200; 18: 191-9. [Crossref]
- 7. Ledebo I, Blankestijn P. Haemodiafiltration-optimal efficiency and safety. NDT Plus 2010; 3: 8-16. [Crossref]
- 8. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck Get, et al. Effects of high-flux hemodialysis on clinical outcomes: Results of the HEMO study. J Am Soc Nephrol 2013; 14: 3251-63. [Crossref]
- 9. Rahmati MA, Homel P, Hoenich NA, Levin R, Kaysen GA, Levin NW. The role of improved water quality on inflammatory markers in patients undergoing regular dialysis. Int J Artif Organs 2004; 27: 723-7. [Crossref]
- 10. Ward RA. Ultrapure dialysate. Semin Dial 2004; 17: 489-97. [Crossref]
- 11. Masakane I. Review: Clinical usefulness of ultrapure dialysate-recent evidence and perspectives. Ther Apher Dial 2006; 10: 348-54. [Crossref]
- 12. Lamas JM, Alonso M, Sastre F, Garcia-Trio G, Saavedra J, Palomares L. Ultrapure dialysate and inflammatory response in haemodialysis evaluated by darbepoetin requirements - a randomized study. Nephrol Dial Transplant 2006; 21: 2851-8. [Crossref]
- 13. Lederer SR, Schiffl H. Ultrapure dialysis fluid lowers the cardiovascular morbidity in patients on maintenance hemodialysis by reducing continuous microinflammation. Nephron 2002; 91: 452-5. [Crossref]
- 14. Canaud B, Bragg-Gresham JL, Marshall MR, Desmeules S, Gillespie BW, Depner T, et al. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006; 69: 2087-93. [Crossref]
- 15. Asci G, Toz H, Ozkahya M, Duman S, Demirci MS, Cirit M, et al. The impact of membrane permeability and dialysate purity on cardiovascular outcomes. J Am Soc Nephrol 2013; 24: 1014-23. [Crossref]
- 16. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340: 115-26. [Crossref]
- 17. Stenvinkel P. Inflammation in end-stage renal failure: Could it be treated? Nephrol Dial Transplant 2002; 17: S33-8. [Crossref]
- 18. Hasegawa T, Nakai S, Masakane I, Watanabe Y, Iseki K, Tsubakihara Y, et al. Dialysis fluid endotoxin level and mortality in maintenance hemodialysis: A nationwide cohort study. Am J Kidney Dis 2015; 65: 899-904. [Crossref]
- 19. Di Iorio B, Di Micco L, Bruzzese D, Nardone L, Russo L, Formisano P, et al. Ultrapure dialysis water obtained with additional ultrafilter may reduce inflammation in patients on hemodialysis. J Nephrol 2017; 30: 795-801. [Crossref]
- 20. Upadhyay A, Jaber BL. We use impure water to make dialysate for hemodialysis. Semin Dial 2016; 29: 297-9. [Crossref]
- 21. Susantitaphong P, Riella C, Jaber BL. Effect of ultrapure dialysate on markers of inflammation, oxidative stress, nutrition and anemia parameters: A meta-analysis. Nephrol Dial Transplant 2013; 28: 438-46. [Crossref]
- 22. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in hemodialysis patients. Nephrol Dial Transplant 2000; 15: 1207-11. [Crossref]
- 23. Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47: 139-48. [Crossref]
- 24. Carrero JJ, Stenvinkel P. Inflammation in end-stage renal disease-What have we learned in 10 years? Semin Dial 2010; 23: 498- 509. [Crossref]
- 25. Docci D, Bilancioni R, Buscaroli A, Baldrati L, Capponcini C, Mengozzi S, et al. Elevated serum levels of C‐reactive protein in hemodialysis patients. Nephron 1990; 56: 364-7. [Crossref]
- 26. Tao J, Sun Y, Li X, Li H, Liu S, Wen Y, et al. Conventional versus ultrapure dialysate for lowering serum lipoprotein(a) levels in patients on long-term hemodialysis: A randomized trial. Int J Artif Organs 2010; 33: 290-6. [Crossref]
- 27. Susantitaphong P, Dember LM, Jaber BL. Dialysis-associated amyloidosis. Picken MM, Herrere GA, Dogan A (eds). Amyloid and Related Disorders: Surgical Pathology and Clinical Correlations. 2nd ed. New York: Humana Press, Springer Science & Business Media, Inc., 2015; p.81-94. [Crossref]
- 28. Locatelli F, Altieri P, Andrulli S, Bolasco P, Sau G, Pedrini LA, et al. Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD. J Am Soc Nephrol 2010; 21: 1798-807. [Crossref]
- 29. Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 2002; 17: 1814-18. [Crossref]
- 30. Upadhyay A, Susantitaphong P, Jaber BL. Ultrapure versus standard dialysate: A cost-benefit analysis. Semin Dial 2017; 30: 398- 402. [Crossref]
- 31. Section IV. Dialysis fluid purity. Nephrol Dial Transplant 2002; 17: 45-62.
- 32. Kawanishi H, Masakane I, Tomo T. The new standard offluids forhemodialysis in Japan. Blood Purif 2009; 27: 5-10. [Crossref]
| APA | dogan i, unal kaya n, kayadibi h (2020). The Effect of Ultrapure Dialysate on Clinical Outcomesand Mortality During One Year Follow-up in PatientsUndergoing Hemodialysis Treatment. , 205 - 211. 10.5152/turkjnephrol.2020.3979 |
| Chicago | dogan ibrahim,unal kaya nur,kayadibi huseyin The Effect of Ultrapure Dialysate on Clinical Outcomesand Mortality During One Year Follow-up in PatientsUndergoing Hemodialysis Treatment. (2020): 205 - 211. 10.5152/turkjnephrol.2020.3979 |
| MLA | dogan ibrahim,unal kaya nur,kayadibi huseyin The Effect of Ultrapure Dialysate on Clinical Outcomesand Mortality During One Year Follow-up in PatientsUndergoing Hemodialysis Treatment. , 2020, ss.205 - 211. 10.5152/turkjnephrol.2020.3979 |
| AMA | dogan i,unal kaya n,kayadibi h The Effect of Ultrapure Dialysate on Clinical Outcomesand Mortality During One Year Follow-up in PatientsUndergoing Hemodialysis Treatment. . 2020; 205 - 211. 10.5152/turkjnephrol.2020.3979 |
| Vancouver | dogan i,unal kaya n,kayadibi h The Effect of Ultrapure Dialysate on Clinical Outcomesand Mortality During One Year Follow-up in PatientsUndergoing Hemodialysis Treatment. . 2020; 205 - 211. 10.5152/turkjnephrol.2020.3979 |
| IEEE | dogan i,unal kaya n,kayadibi h "The Effect of Ultrapure Dialysate on Clinical Outcomesand Mortality During One Year Follow-up in PatientsUndergoing Hemodialysis Treatment." , ss.205 - 211, 2020. 10.5152/turkjnephrol.2020.3979 |
| ISNAD | dogan, ibrahim vd. "The Effect of Ultrapure Dialysate on Clinical Outcomesand Mortality During One Year Follow-up in PatientsUndergoing Hemodialysis Treatment". (2020), 205-211. https://doi.org/10.5152/turkjnephrol.2020.3979 |
| APA | dogan i, unal kaya n, kayadibi h (2020). The Effect of Ultrapure Dialysate on Clinical Outcomesand Mortality During One Year Follow-up in PatientsUndergoing Hemodialysis Treatment. Turkish journal of nephrology (Online), 29(3), 205 - 211. 10.5152/turkjnephrol.2020.3979 |
| Chicago | dogan ibrahim,unal kaya nur,kayadibi huseyin The Effect of Ultrapure Dialysate on Clinical Outcomesand Mortality During One Year Follow-up in PatientsUndergoing Hemodialysis Treatment. Turkish journal of nephrology (Online) 29, no.3 (2020): 205 - 211. 10.5152/turkjnephrol.2020.3979 |
| MLA | dogan ibrahim,unal kaya nur,kayadibi huseyin The Effect of Ultrapure Dialysate on Clinical Outcomesand Mortality During One Year Follow-up in PatientsUndergoing Hemodialysis Treatment. Turkish journal of nephrology (Online), vol.29, no.3, 2020, ss.205 - 211. 10.5152/turkjnephrol.2020.3979 |
| AMA | dogan i,unal kaya n,kayadibi h The Effect of Ultrapure Dialysate on Clinical Outcomesand Mortality During One Year Follow-up in PatientsUndergoing Hemodialysis Treatment. Turkish journal of nephrology (Online). 2020; 29(3): 205 - 211. 10.5152/turkjnephrol.2020.3979 |
| Vancouver | dogan i,unal kaya n,kayadibi h The Effect of Ultrapure Dialysate on Clinical Outcomesand Mortality During One Year Follow-up in PatientsUndergoing Hemodialysis Treatment. Turkish journal of nephrology (Online). 2020; 29(3): 205 - 211. 10.5152/turkjnephrol.2020.3979 |
| IEEE | dogan i,unal kaya n,kayadibi h "The Effect of Ultrapure Dialysate on Clinical Outcomesand Mortality During One Year Follow-up in PatientsUndergoing Hemodialysis Treatment." Turkish journal of nephrology (Online), 29, ss.205 - 211, 2020. 10.5152/turkjnephrol.2020.3979 |
| ISNAD | dogan, ibrahim vd. "The Effect of Ultrapure Dialysate on Clinical Outcomesand Mortality During One Year Follow-up in PatientsUndergoing Hemodialysis Treatment". Turkish journal of nephrology (Online) 29/3 (2020), 205-211. https://doi.org/10.5152/turkjnephrol.2020.3979 |
